Sevoflurane Vaporizer

Sevoflurane Vaporizer

Product Details:

  • Drug Type Specific Drug
  • Physical Form Liquid
  • Dosage As Directed By Physician
  • Dosage Guidelines As Directed By Physician
  • Storage Instructions Store In a Cool & Dry Place
  • Supply Ability : 1000 Bottle Per Month
27-30 USD ($)/Bottle
X

Price And Quantity

  • 1000 Bottle
  • 27-30 USD ($)/Bottle

Product Specifications

  • Specific Drug
  • As Directed By Physician
  • Liquid
  • As Directed By Physician
  • Store In a Cool & Dry Place

Trade Information

  • ALL INDIA
  • Paypal, Western Union, Cash in Advance (CID), Cash Advance (CA)
  • 1000 Bottle Per Month
  • 2-3 Week
  • Yes
  • Sample costs shipping and taxes has to be paid by the buyer
  • 50 ml, 250 ml
  • Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia
  • All India
  • WHO,GMP,COA As per client requirement

Product Description

Sevoflurane (1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane; synonym, fluoromethyl hexafluoroisopropyl ether), is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used as an inhalational anaesthetic for induction and maintenance of general anesthesia. After desflurane, it is the volatile anesthetic with the fastest onset and offset.

It is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, across all ages, as well as in veterinary medicine. Together with desflurane, sevoflurane is replacing isoflurane and halothane in modern anesthesiology. It is often administered in a mixture of nitrous oxide and oxygen.

Sevoflurane has an excellent safety record, but is under review for potential neurotoxicity, especially relevant to administration in infants and children, and rare reports similar to halothane hepatotoxicity. Sevoflurane is the preferred agent for mask induction due to its lesser irritation to mucous membranes.

Sevoflurane was discovered by Ross Terrel and independently by Bernard M Regan. A detailed report of its development and properties appeared in 1975 in a paper authored by Richard Wallin, Bernard Regan, Martha Napoli and Ivan Stern. It was introduced into clinical practice initially in Japan in 1990 by Maruishi Pharmaceutical Co., Ltd. Osaka, Japan. The rights for sevoflurane worldwide were held by AbbVie. It is now available as a generic drug.

Additional Information

The most widely recognized markets for this item incorporate the accompanying nations. you don't mind ask with us if your nation or district isn't recorded:

ASIA: Afghanistan, Israel, Jordan, Pakistan, Russia, Saudi Arabia, Singapore, Syria, Philippines, Turkey, Turkmenistan, Uzbekistan, Yemen, Vietnam, Indonesia, Malaysia, Iran, Tajikistan, and so forth.

AFRICA: South Africa, Uganda, Nigeria, Ghana, Kenya, Mauritius, Botswana, Egypt, Ethiopia, Libya, Sudan, Congo, Gambia, Ivory Coast , and so forth.

NORTH & SOUTH AMERICA: USA, Canada, Panama, Trinidad and Tobago, Costa Rica, Puerto Rico, Dominican Republic, Argentina, Guatemala, Guyana, Peru, Bolivia, Venezuela , Brazil, Bahamas, Ecuador, and so forth .

EUROPE: Austria , Azerbaijan, Belarus, Belgium, Cyprus, Czech Republic, Denmark, France, Georgia, Germany, Hungary, Ireland, Iceland, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Ukraine, United Kingdom (UK) , Latvia, and so forth.

OCEANIA: Australia, New Zealand, Fiji, and so forth.


WHITE SWAN PHARMACEUTICAL

* Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.



Back to top
WHITE SWAN PHARMACEUTICAL All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Ltd.